On the other hand, gene coexpression analysis demonstrated that tumors with a CD133 coexpression module signature (CD133-CMS) are enriched for the proneural GBM subtype, which shows enhanced proliferation, and those with the CD44 coexpression module signature (CD44-CMS) are enriched for the mesenchymal subtype and show enhanced invasion. The gene discussed is PROM1; the disease is glioblastoma.